Published in Target Oncol on March 08, 2012
The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23
Ubiquitin in the immune system. EMBO Rep (2013) 1.06
Bacteria in Cancer Therapy: Renaissance of an Old Concept. Int J Microbiol (2016) 0.95
Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immune responses. Am J Clin Exp Immunol (2013) 0.92
Toll-like Receptors in Ovarian Cancer as Targets for Immunotherapies. Front Immunol (2014) 0.88
Toll-like receptors in urothelial cells--targets for cancer immunotherapy. Nat Rev Urol (2013) 0.85
Adjuvant for vaccine immunotherapy of cancer - focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity. Cancer Sci (2015) 0.84
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. Immunol Endocr Metab Agents Med Chem (2012) 0.84
Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy. Oncoimmunology (2016) 0.81
Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment. Breast Cancer (Dove Med Press) (2013) 0.81
Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94. Curr Top Med Chem (2016) 0.79
Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer. Int J Clin Exp Pathol (2015) 0.79
Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system. Mol Cancer (2014) 0.78
IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women. Front Immunol (2013) 0.78
Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer. Front Immunol (2013) 0.78
Future directions in bladder cancer immunotherapy: towards adaptive immunity. Immunotherapy (2016) 0.77
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
Human parainfluenza virus type 2 vector induces dendritic cell maturation without viral RNA replication/transcription. Hum Gene Ther (2013) 0.75
Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells. Oncotarget (2016) 0.75
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med (2005) 3.59
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31
Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity (2006) 2.62
Chemokines in cancer. Cytokine Growth Factor Rev (2002) 2.47
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 2.25
Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J Immunol (2005) 2.05
Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem (2005) 2.03
Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest (2010) 1.88
Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol (2006) 1.68
Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol (2007) 1.64
The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes (2009) 1.63
The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med (2003) 1.63
Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J Immunol (2002) 1.55
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol (2006) 1.55
Identification of mouse langerin/CD207 in Langerhans cells and some dendritic cells of lymphoid tissues. J Immunol (2002) 1.53
Disruption of the langerin/CD207 gene abolishes Birbeck granules without a marked loss of Langerhans cell function. Mol Cell Biol (2005) 1.45
Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. Eur J Immunol (2002) 1.44
Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol (2002) 1.38
CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol (2005) 1.37
Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res (2009) 1.35
Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol (2007) 1.32
Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol (2006) 1.29
Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26
Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol (2010) 1.25
Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res (2011) 1.24
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res (2011) 1.23
ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res (2012) 1.22
High diversity of the immune repertoire in humanized NOD.SCID.gamma c-/- mice. Eur J Immunol (2009) 1.19
Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci U S A (2007) 1.19
Chemokine receptor CCR2 but not CCR5 or CCR6 mediates the increase in pulmonary dendritic cells during allergic airway inflammation. J Immunol (2007) 1.17
TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res (2011) 1.14
TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol (2010) 1.13
Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One (2011) 1.11
Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res (2013) 1.11
Network of dendritic cells within the muscular layer of the mouse intestine. Proc Natl Acad Sci U S A (2005) 1.10
Targeting regulatory T cells. Target Oncol (2012) 1.10
High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology (2006) 1.09
Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol (2011) 1.09
Lipoteichoic acid increases TLR and functional chemokine expression while reducing dentin formation in in vitro differentiated human odontoblasts. J Immunol (2006) 1.07
Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res (2004) 1.07
MHC class II compartments in human dendritic cells undergo profound structural changes upon activation. Traffic (2002) 1.06
CD208/dendritic cell-lysosomal associated membrane protein is a marker of normal and transformed type II pneumocytes. Am J Pathol (2004) 1.06
Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts. Eur J Immunol (2004) 1.06
Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology (2012) 1.05
Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol Pharmacol (2003) 1.05
Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin. Blood (2003) 1.03
Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. Int J Cancer (2004) 1.00
OSCAR is an FcRgamma-associated receptor that is expressed by myeloid cells and is involved in antigen presentation and activation of human dendritic cells. Blood (2004) 1.00
In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol (2008) 0.99
Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res (2007) 0.99
Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res (2005) 0.97
CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected]. J Immunol (2010) 0.95
Odontoblasts in the dental pulp immune response. J Exp Zool B Mol Dev Evol (2009) 0.95
The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol (2013) 0.94
Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology (2012) 0.91
Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit Langerhans cell development. J Immunol (2002) 0.90
The class 6 semaphorin SEMA6A is induced by interferon-gamma and defines an activation status of langerhans cells observed in pathological situations. Am J Pathol (2006) 0.89
Cleaved/associated TLR3 represents the primary form of the signaling receptor. J Immunol (2012) 0.89
MyD88 and its divergent toll in carcinogenesis. Trends Immunol (2013) 0.88
Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer (2011) 0.88
MyD88 in DNA repair and cancer cell resistance to genotoxic drugs. J Natl Cancer Inst (2013) 0.87
NF-kappaB protects human papillomavirus type 38 E6/E7-immortalized human keratinocytes against tumor necrosis factor alpha and UV-mediated apoptosis. J Virol (2011) 0.87
Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. Eur J Cancer (2012) 0.86
CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. Blood (2011) 0.86
Functional analysis of the exported type IV HSP40 protein PfGECO in Plasmodium falciparum gametocytes. Eukaryot Cell (2011) 0.85
Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol (2004) 0.84
Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology (2013) 0.84
Cloning and characterization of the mouse homologue of the human dendritic cell maturation marker CD208/DC-LAMP. Eur J Immunol (2003) 0.84
Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. Oncoimmunology (2012) 0.84
Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells. Int J Cancer (2013) 0.83
Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production. J Leukoc Biol (2005) 0.83
p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells. Biochem Pharmacol (2007) 0.83
E7 properties of mucosal human papillomavirus types 26, 53 and 66 correlate with their intermediate risk for cervical cancer development. Virology (2007) 0.82
In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. Novartis Found Symp (2004) 0.82
Fc receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses. Blood (2005) 0.82
Human papillomavirus type 16 E6 inhibits p21(WAF1) transcription independently of p53 by inactivating p150(Sal2). Virology (2011) 0.82
CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer (2012) 0.80
ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells. Oncoimmunology (2013) 0.80
Management of occult fractures in the skeletally immature patient: cost analysis of implementing a limited trauma magnetic resonance imaging protocol. Pediatr Emerg Care (2009) 0.80
Critical role of ITIM-bearing FcgammaR on DCs in the capture and presentation of native antigen to B cells. Immunity (2005) 0.79
Immunohistochemical tracking of an immune response in mammary Paget's disease. Cancer Lett (2008) 0.79
Recent successes of cancer immunotherapy: a new dimension in personalized medicine? Target Oncol (2012) 0.79
MIP-3alpha/CCL20 in renal transplantation and its possible involvement as dendritic cell chemoattractant in allograft rejection. Am J Transplant (2005) 0.79
Langerhans cells: still a fundamental paradigm for studying the immunobiology of dendritic cells. Trends Immunol (2002) 0.78
Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int J Cancer (2014) 0.77
Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. Target Oncol (2013) 0.77
Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. Blood (2012) 0.77
Pillars Article: Differentiation of Monocytes into Dendritic Cells in a Model of Transendothelial Trafficking. Science. 1998. 282: 480-483. J Immunol (2017) 0.75
Allogeneic reaction induces dendritic cell maturation through proinflammatory cytokine secretion. Transplantation (2004) 0.75
Toll-like receptor 3 (TLR3): a new marker of canine monocytes-derived dendritic cells (cMo-DC). Vet Immunol Immunopathol (2007) 0.75
[PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]. Bull Cancer (2012) 0.75